Endonovo Therapeutics, Inc. (ENDV) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Woodland Hills, CA, United States. The current CEO is Alan Brian Collier.
ENDV has IPO date of 2012-11-15, 1 full-time employees, listed on the Other OTC, a market capitalization of $31.88K.
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
